Immunotherapy has changed first-line treatment for mismatch repair-deficient endometrial cancer, but trials have never tested dropping chemotherapy from the regimen.
Doctors question chemotherapy for some advanced endometrial cancer patients
Immunotherapy has changed first-line treatment for mismatch repair-deficient endometrial cancer, but trials have never tested dropping chemotherapy from the regimen.
![[Comment] Is chemotherapy still needed in all patients with mismatch repair-deficient advanced or recurrent endometrial cancer?](https://nbg1.your-objectstorage.com/ckln/image-assets/318648f55a0ce245a9f3f9c52a953dbd4c36cdd492cc19a5c52b7604dbf2d3c8.jpg)
Blausen Medical Communications, Inc. · CC BY 3.0 · rights
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.